Dr Reddy’s Laboratories has entered into an agreement with Eli Lilly and Company for the manufacture and commercialization of Baricitinib in India, the Hyderabad-based pharma company said on Tuesday.
Baricitinib is to be used in the treatment of suspected or laboratory-confirmed Covid-19 infections in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
The drug has received restricted emergency use approval from the Central Drugs Standard Control Organisation (CDSCO) for use in combination with Remdesivir.
Dr Reddy’s said, “This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company’s existing range of Covid-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine.”
“From the start, we have been determined to explore every possible avenue against Covid-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India,” the firm’s CEO (API and Services) Deepak Sapra said.
Eli Lilly and Company had on 10 May announced voluntary licensing agreements with Sun Pharma, Cipla and Lupin to expedite the availability of Baricitinib for treatment of Covid-19 patients in India.